ClinicalTrials.gg
RecruitingNCT05671822Updated Feb 12, 2026

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

A Phase 2 interventional study of SHR-A1811 and SHR-1701 and SHR-A1811 and capecitabine in HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 5 under way, 2 of them phase 3. Stomach Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
6th of 14
258 · median 151
Started
2023
the only one that year
Phase 2
4 of 14
3 open now
Registered
11th of 14
by date

Among the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by planned enrollment, is the only one that started in 2023, is one of 4 in phase 2, and was the 11th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

5 of the 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stomach Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy and/or immunotherapy in HER2 expression advanced/metastatic gastric/gastroesophageal junction adenocarcinoma patients.

The Phase II study was designed to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and/or immunotherapy for advanced/metastatic HER2 expression gastric/gastroesophageal conjunctional adenocarcinoma patients.

03

Conditions studied

  • HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age from 18 to 75, Male and female participants
  2. Local advanced unresectable or disease documented adenocarcinoma of gastric or gastroesophageal junction;
  3. expression ;
  4. Phase Ib: Failed or intolerant to prior standard treatment, or did not receive any systemic anti-tumor therapy; Phase II: previously untreated patients;
  5. 0-1;
  6. The expected survival ≥3 months;
  7. Sufficient bone marrow and organ functions;

Exclusion criteria

Exclusion Criteria:

  1. There were ascites, pleural effusion and pericardial effusion that needed to be treated;
  2. Major surgery was performed within 4 weeks;
  3. Have active disease or history of autoimmune disease;
  4. Patients with interstitial pneumonia;
  5. There was severe infection within 4 weeks before starting the study treatment;
  6. Patients with active pulmonary tuberculosis infection history within 1 year before enrollment;
  7. Serious cardiovascular and cerebrovascular diseases;
  8. Gastrointestinal perforation and/or gastrointestinal fistula occurred within 6 months before enrollment;
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    Arm 1A: SHR-A1811 and SHR-1701

    Drug: SHR-A1811 and SHR-1701

  • Experimental
    Arm 1B: SHR-A1811 and capecitabine

    Drug: SHR-A1811 and capecitabine

  • Experimental
    Arm 1C: SHR-A181, SHR-1701, and capecitabine

    Drug: SHR-A181, SHR-1701, and capecitabine

  • Experimental
    Arm 1D: SHR-A1811, SHR-1316, and capecitabine

    Drug: SHR-A1811, SHR-1316, and capecitabine

  • Experimental
    Arm 1F: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin

    Drug: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin

  • Experimental
    Arm 1G: SHR-A1811, SHR-1316, and 5-FU

    Drug: SHR-A1811, SHR-1316, and 5-FU

  • Experimental
    Arm 2A: SHR-A1811, SHR-1316, and capecitabine

    Drug: SHR-A1811, SHR-1316, and capecitabine

  • Experimental
    Arm 2B: SHR-1316 and SHR-A181

    Drug: SHR-1316 and SHR-A1811

  • Experimental
    Arm 2C: SHR-A1811 and capecitabine

    Drug: SHR-A1811 and capecitabine

  • Experimental
    Arm 2D: SHR-A1811, SHR-1316, and 5-FU

    Drug: SHR-A1811, SHR-1316, and 5-FU

  • Experimental
    Arm 2E: SHR-A1811and 5-FU

    Drug: SHR-A1811and 5-FU

  • Experimental
    Arm 2F: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin

    Drug: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin

Interventions

  • DrugSHR-A1811 and SHR-1701

    Drug pages: Trastuzumab rezetecan · SHR-1701

    (Arm 1A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion;

  • DrugSHR-A1811 and capecitabine

    Drug pages: Trastuzumab rezetecan · Capecitabine

    (Arm 1B) Drug: SHR-A1811, administered as an IV infusion Drug:capecitabine, administered orally;

  • DrugSHR-A181, SHR-1701, and capecitabine

    (Arm 1C) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug:capecitabine, administered orally;

  • DrugSHR-A1811, SHR-1316, and capecitabine

    (Arm 1D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:capecitabine, administered orally;

  • DrugSHR-A1811, SHR-1316, capecitabine,and oxaliplatin

    (Arm 1F) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:capecitabine, administered orally; Drug:oxaliplatin,administered as an IV infusion

  • DrugSHR-A1811, SHR-1316, and 5-FU

    (Arm 1G) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:5-FU,administered as an IV infusion

  • DrugSHR-A1811, SHR-1316, and capecitabine

    (Arm 2A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316 administered as an IV infusion; Drug:capecitabine, administered orally;

  • DrugSHR-1316 and SHR-A1811

    Drug pages: Adebrelimab · Trastuzumab rezetecan

    (Arm 2B) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion

  • DrugSHR-A1811 and capecitabine

    Drug pages: Trastuzumab rezetecan · Capecitabine

    (Arm 2C) Drug: SHR-A1811, administered as an IV infusion Drug:capecitabine, administered orally;

  • DrugSHR-A1811, SHR-1316, and 5-FU

    (Arm 2D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:5-FU,administered as an IV infusion

  • DrugSHR-A1811and 5-FU

    (Arm 2E) Drug: SHR-A1811, administered as an IV infusion Drug:5-FU,administered as an IV infusion

  • DrugSHR-A1811, SHR-1316, capecitabine,and oxaliplatin

    (Arm 2F) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug:capecitabine, administered orally; Drug:oxaliplatin,administered as an IV infusion

06

What researchers measure

Primary outcomes

  1. Phase Ib: Dose limiting toxicity (DLT) rates, Occurrence of adverse events (AEs), and serious adverse events (SAEs)

    Time frame: Safety will be assessed for approximately 24 months from informed consent

  2. Phase II: Objective Response Rate (ORR)[

    Time frame: An average of approximately 12 months

Secondary outcomes

  1. ORR(Phase Ib)

    Time frame: An average of approximately 12 months

  2. DoR(Phase Ib)

    Time frame: An average of approximately 18 months

  3. PFS(Phase Ib)

    Time frame: An average of approximately 18 months

  4. OS(Phase Ib)

    Time frame: An average of approximately 30 months

  5. DoR(Phase II)

    Time frame: An average of approximately 18 months

  6. PFS(Phase II)

    Time frame: An average of approximately 18 months

  7. OS(Phase II)

    Time frame: An average of approximately 30 months

  8. Occurrence of adverse events (AEs), and serious adverse events (SAEs) (Phase II)

    Time frame: Safety will be assessed for approximately 24 months from informed consent]

07

Study locations

1 of 1 sites recruiting
  • Zhongshan Hospital, FuDan University
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Tianshu Liu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 57 months is above that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2023
First posted
Jan 5, 2023
StartActual
Mar 14, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05671822
Responsible party
Sponsor
First posted
Jan 5, 2023
Start date
Mar 14, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Shiwei Sun
Contact
Shiwei.sun@hengrui.com
+86 18036618554

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · SHR-1701 · Capecitabine · Adebrelimab

Start the discussion